Back to first-pass browser

First-pass extracted concept

cell-mediated delivery systems

Candidate: concept label1 source documents5 linked claims
Jump to explainersJump to evidenceJump to sourcesJump to claims
Live refresh every 5sNext refresh in 5s

Extracted Explainers

What the tool is doing

This concept covers delivery platforms that use living cells as carriers to transport therapeutic agents to specific tissues or across difficult biological barriers. The abstract frames them as targeted delivery systems with intracellular and tissue-specific relevance.

Source 1DOIPubMed

Resources required

The abstract indicates these systems depend on engineered cellular carriers and supporting molecular engineering. Specific carrier subclasses or manufacturing details are not given in the provided text.

Source 1DOIPubMed

What problem it solves

They address delivery across restrictive environments such as the blood-brain barrier and tumor microenvironment. They are also presented as improving tissue targeting and intracellular access.

Source 1DOIPubMed

What it does not solve

The abstract states that scalability, manufacturing, safety, and regulatory approval remain unresolved challenges. It does not claim these systems fully solve translational deployment.

Source 1DOIPubMed

Alternatives

The source contrasts cell-mediated systems with peptide-assisted delivery systems and hybrid nanostructures as parallel platform classes.

Source 1DOIPubMed

Evidence Snippets

Cell-mediated and peptide-assisted delivery systems have emerged as powerful platforms... By leveraging the intrinsic targeting, transport, and signaling capacities of living cells...
Evidence 1Source 1DOIPubMedprovenance

Supporting Sources

Linked Claims

Claim 1capabilitysupports2025Source 1DOIPubMed

Cell-mediated and peptide-assisted delivery systems facilitate delivery of therapeutic agents across restrictive biological barriers such as the blood-brain barrier and the tumor microenvironment.

Quoted textsource-backed
By leveraging the intrinsic targeting, transport, and signaling capacities of living cells and bioinspired peptides, these systems facilitate the delivery of therapeutic agents across otherwise restrictive biological barriers such as the blood-brain barrier (BBB) and the tumor microenvironment.
Claim 2limitationsupports2025Source 1DOIPubMed

Cell-mediated and peptide-assisted delivery technologies still face challenges in scalability, manufacturing, safety, and regulatory approval.

Quoted textsource-backed
Despite notable advances, challenges remain in scalability, manufacturing, safety, and regulatory approval.
Claim 3mechanistic or performancesupports2025Source 1DOIPubMed

Advanced peptide designs and engineered cellular carriers have enabled improved BBB penetration, enhanced tumor homing, and more efficient cytosolic delivery.

Quoted textsource-backed
Key innovations include improved BBB penetration, enhanced tumor homing, and more efficient cytosolic delivery enabled by advanced peptide designs and engineered cellular carriers.
Claim 4progress summarysupports2025Source 1DOIPubMed

Current cell-based transport systems, peptide conjugates, and multifunctional nanostructures have shown significant progress for targeted delivery of drugs, nucleic acids, and immunomodulatory agents.

Quoted textsource-backed
Analysis of current strategies reveals significant progress in optimizing cell-based transport systems, peptide conjugates, and multifunctional nanostructures for the targeted delivery of drugs, nucleic acids, and immunomodulatory agents.
Claim 5translational statussupports2025Source 1DOIPubMed

Several cell-mediated and peptide-assisted delivery platforms have progressed toward clinical translation.

Quoted textsource-backed
Several platforms have progressed toward clinical translation, underscoring their therapeutic potential.